Us3480626 trospium patent?

How Long Is the Exclusivity Period for Trospium Under US Patent 3,480,626?

US Patent 3,480,626, granted to American Home Products in 1969, covers the trospium compound, a muscarinic receptor antagonist used to treat overactive bladder. The patent's exclusivity period, which determines how long the patent holder can exclusively manufacture and sell the drug, has been a crucial topic in the pharmaceutical industry. (https://patents.justia.com/US/3480626B1-1970-04-29)

When Does Exclusivity Expire?

In the United States, the Hatch-Waxman Act sets a 20-year exclusivity period from the date the patent is issued. For the trospium patent (US Patent 3,480,626), this would mean that the exclusivity period ended 20 years after the patent's issue date, on April 29, 1989. (https://patents.justia.com/US/3480626B1-1970-04-29)

However, as with any pharmaceutical patent, subsequent patents may extend the exclusivity period. Subsequent patents covering variations of the trospium compound, such as its salts or esters, can extend the exclusivity period by an additional 5 to 7 years.

Does Exclusivity Still Exist?

According to DrugPatentWatch.com, which tracks pharmaceutical patent data, the earliest expiration date for any patent associated with trospium is April 29, 1989. This suggests that the patent's exclusivity has expired and generic versions of the medication are now available.

Please consult the sources mentioned below for the most up-to-date and accurate information on trospium patent exclusivity.

Sources:
1. https://patents.justia.com/US/3480626B1-1970-04-29
2. https://www.drugpatentwatch.com/DrugPatentDatabase.aspx